Skip to main content

Verteporfin Pregnancy and Breastfeeding Warnings

Medically reviewed by Last updated on Jul 5, 2022.

Verteporfin is also known as: Visudyne

Verteporfin Pregnancy Warnings

Animal studies have revealed evidence of embryotoxicity and teratogenicity. There are no controlled data in human pregnancy. It is not known whether this drug can cause fetal harm or adversely affect reproductive capacity in humans.

AU TGA pregnancy category B3: Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed. Studies in animals have shown evidence of an increased occurrence of fetal damage, the significance of which is considered uncertain in humans.

US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D and X are being phased out.

This drug should be used during pregnancy only if the benefit outweighs the risk.

AU TGA pregnancy category: B3
US FDA pregnancy category: Not assigned.

Risk Summary: When this drug was given to pregnant animals during the period of organogenesis there was an increase in the incidence of anophthalmia/microphthalmia and wavy ribs at exposures approximately 40-fold the human exposure at the recommended dose.

-Adequate methods of contraception should be encouraged.
-If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus.

See references

Verteporfin Breastfeeding Warnings

Use should be avoided.

Excreted into human milk: Yes

-The effects in the nursing infant are unknown.
-Withholding breastfeeding for 24 to 48 hours after this drug has been administered should minimize risk to the breastfed infant.

See references

References for pregnancy information

  1. "Product Information. Visudyne (verteporfin)." Valeant Pharmaceuticals (2001):

References for breastfeeding information

  1. "Product Information. Visudyne (verteporfin)." Valeant Pharmaceuticals (2001):

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.